Marksans Pharma raises Rs. 372.40 crores
OrbiMed's exercise of warrant conversion will further strengthen the company's net cash position to over Rs.650 crores.
OrbiMed's exercise of warrant conversion will further strengthen the company's net cash position to over Rs.650 crores.
Multilateral collaborations will serve to strengthen knowledge sharing to formulate framework for accessible, affordable, and quality healthcare
The issue with a face value of Rs 10 per equity share consists of a fresh issue of equity shares worth up to Rs 400 crore
The company will not receive any proceeds from the offer as all of it will go to the promoter selling shareholder.
Connectivity and harmonisation were both key driving factors behind our decision to choose the CARA Life Sciences Platform to consolidate our processes
Valentas and Arnipin are indicated to reduce repeated hospitalization and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure
Point-of-Care solution to facilitate clinicians in quick and effective decision making
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
A First of its Kind Initiative in Mahbubnagar District for Medical Officers, ANM, Anganwadi workers for prevention of Thalassemia and Sickle Cell anemia as part of Antenatal screening of pregnant women project
Under the soon to be launched Heal in India initiative, India aims to provide its health infrastructure for patients abroad and make it a global hub for medical and value-based healthcare for patients from across the world
Subscribe To Our Newsletter & Stay Updated